Skip to search formSkip to main contentSkip to account menu

CancerVax

Known as: C-VAX 
CancerVax is an allogenic polyvalent vaccine composed of irradiated but viable cells from three melanoma cell lines and Bacille Calmette-Guerin (BCG… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2012
2012
volume 30 number 4 APrIl 2012 nature biotechnology “It’s pioneering technology based on a simple, elegant concept,” enthuses… 
2007
2007
BackgroundWe have observed prolonged survival in patients undergoing vaccine reinduction after resection of recurrent metastatic… 
2006
2006
AbstractBackground: Case control studies have demonstrated that administration of CancerVax, a polyvalent melanoma cell vaccine… 
2004
2004
  • S. Motl
  • Current opinion in molecular therapeutics
  • 2004
  • Corpus ID: 20197131
CancerVax and the John Wayne Cancer Institute are co-developing Biotechnology Tumor antigen Canvaxin, a vaccine containing over… 
2003
2003
PURPOSE A therapeutic polyvalent cancer vaccine (Canvaxin vaccine; CancerVax Corp, Carlsbad, CA) induces antibodies to a… 
Highly Cited
2002
Highly Cited
2002
PURPOSE The curative effect of surgery in certain patients with metastatic melanoma suggests the presence of endogenous antitumor… 
Highly Cited
2002
Highly Cited
2002
PURPOSE Although the improved overall survival (OS) of patients who receive Canvaxin (CancerVax Corp, Carlsbad, CA) polyvalent… 
Highly Cited
2001
Highly Cited
2001
AbstractBackground: The immunogenicity of the polyvalent tumor cell vaccine CancerVax has been correlated with the survival of… 
2001
2001
Introduction: TA90 is a tumor-associated 90-kD glycoprotein antigen expressed on most melanoma cells, including those of… 
Highly Cited
1998
Highly Cited
1998
PURPOSE The mechanisms that underlie the clinical efficacy of melanoma vaccines are not well understood. We hypothesized that the…